Pulmatrix Inc

-0.02 (-2.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)33.75M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.18 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$0.65
50-Day MA$0.75
200-Day MA$0.95
See more pivots

Pulmatrix Inc Stock, NASDAQ:PULM

99 Hayden Avenue, Suite 390, Lexington, Massachusetts 02421
United States of America
Phone: +1.781.357.2333
Number of Employees: 20


Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.